Why direct-to-consumer sales are unlikely to significantly lower drug costs

Pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Bristol Myers Squibb, are increasingly exploring direct-to-consumer (DTC) drug sales, a model supported by former President Trump and dubbed 'pharm-to-table' by some in the industry. However, health policy experts caution that despite industry enthusiasm, this approach is unlikely to significantly lower drug prices for most consumers, as pharma-offered cash prices remain higher than insurance-negotiated rates and DTC purchases do not contribute to patient deductibles or out-of-pocket maximums, potentially increasing overall patient costs.

Analysis

Major pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Bristol Myers Squibb, are actively implementing direct-to-consumer (DTC) sales channels for key drugs like Ozempic and Eliquis, a strategy that has also received verbal support from Pfizer and AstraZeneca. This "pharm-to-table" model is being positioned as a response to political pressure on drug pricing by offering discounted cash prices directly to patients. However, analysis from health policy and pricing experts suggests this approach is unlikely to provide widespread consumer relief. The core issues are twofold: the direct cash prices, while discounted, are expected to remain substantially higher than insurance-negotiated rates, and these out-of-pocket payments will not count toward patients' annual deductibles or out-of-pocket maximums. This structure could paradoxically increase a patient's total annual healthcare expenditure, undermining the model's affordability premise and limiting its appeal primarily to the uninsured or those with very high-deductible plans. The moderately negative sentiment reflects skepticism that this strategy is a sustainable solution to pricing pressure rather than a niche marketing and public relations effort.

Key Decisions for Investors

• Investors should treat the revenue potential from these DTC channels with caution, as the model's structural limitations—namely high cash prices and exclusion from insurance benefit accumulators—are likely to constrain the size of the addressable market.
• Monitor for potential reputational risk for firms like LLY, NVO, and BMY, as the 'pharm-to-table' narrative could face backlash from consumers and policymakers if it fails to deliver meaningful cost savings as highlighted by industry experts.
• Consider the strategic implications of bypassing pharmacy benefit managers (PBMs) and insurers, as this could trigger shifts in formulary negotiations or competitive responses that may affect long-term profitability and market access for the involved drugs.